Immutep Receives €2.59mln R&D Tax Incentive Payment from French Government.

Immutep Limited, a late-stage immunotherapy company, received a €2,588,954 (~ A$4,567,769) research and development tax incentive payment from the French Government under its Crédit d’Impôt Recherche scheme. The payment is in respect of eligible R&D activities conducted in the European Union in 2024. Immutep qualifies for the tax incentive through its subsidiary Immutep S.A.S. due to research and development conducted in its French laboratory.